KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Current Deferred Revenue (2021 - 2024)

Historic Current Deferred Revenue for Travere Therapeutics (TVTX) over the last 4 years, with Q4 2024 value amounting to $2.8 million.

  • Travere Therapeutics' Current Deferred Revenue fell 6848.06% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year decrease of 6848.06%. This contributed to the annual value of $2.8 million for FY2024, which is 6848.06% down from last year.
  • Per Travere Therapeutics' latest filing, its Current Deferred Revenue stood at $2.8 million for Q4 2024, which was down 6848.06% from $3.8 million recorded in Q3 2024.
  • Travere Therapeutics' Current Deferred Revenue's 5-year high stood at $36.6 million during Q4 2021, with a 5-year trough of $2.8 million in Q4 2024.
  • Moreover, its 4-year median value for Current Deferred Revenue was $10.6 million (2023), whereas its average is $12.2 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 1806.77% in 2023, then tumbled by 6848.06% in 2024.
  • Over the past 4 years, Travere Therapeutics' Current Deferred Revenue (Quarter) stood at $36.6 million in 2021, then plummeted by 37.49% to $22.9 million in 2022, then plummeted by 61.01% to $8.9 million in 2023, then tumbled by 68.48% to $2.8 million in 2024.
  • Its Current Deferred Revenue stands at $2.8 million for Q4 2024, versus $3.8 million for Q3 2024 and $5.4 million for Q2 2024.